

Michał, Biełkowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6841285/publications.pdf>

Version: 2024-02-01

44
papers

545
citations

759055

12
h-index

752573

20
g-index

50
all docs

50
docs citations

50
times ranked

1279
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence. <i>Cancer Treatment Reviews</i> , 2022, 104, 102359.	3.4	9
2	Comprehensive cancer-oriented biobanking resource of human samples for studies of post-zygotic genetic variation involved in cancer predisposition. <i>PLoS ONE</i> , 2022, 17, e0266111.	1.1	4
3	Impact of Activation of EGFL7 within Microenvironment of High Grade Ovarian Serous Carcinoma on Infiltration of CD4+ and CD8+ Lymphocytes. <i>Medicina (Lithuania)</i> , 2022, 58, 588.	0.8	1
4	miRNA signatures of prognostic significance in single hormone receptor-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e12544-e12544.	0.8	0
5	Who Is a Pathologist According to Oncology Patients and Internet Users? A Survey Study. <i>Journal of Cancer Education</i> , 2021, 36, 370-376.	0.6	1
6	Plasma amino acids indicate glioblastoma with ATRX loss. <i>Amino Acids</i> , 2021, 53, 119-132.	1.2	8
7	Combined Assessment of Immune Checkpoint Regulator VISTA on Tumor-Associated Immune Cells and Platelet-to-Lymphocyte Ratio Identifies Advanced Germ Cell Tumors with Higher Risk of Unfavorable Outcomes. <i>Cancers</i> , 2021, 13, 1750.	1.7	12
8	Impact of relative dose intensity of oxaliplatin in adjuvant therapy among stage III colon cancer patients on early recurrence: a retrospective cohort study. <i>BMC Cancer</i> , 2021, 21, 529.	1.1	9
9	Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score 2: Systematic review and meta-analysis. <i>Lung Cancer</i> , 2021, 158, 97-106.	0.9	31
10	The Role of Urine F2-isoprostane Concentration in Delayed Cerebral Ischemia after Aneurysmal Subarachnoid Haemorrhage: A Poor Prognostic Factor. <i>Diagnostics</i> , 2021, 11, 5.	1.3	7
11	Diagnostic Accuracy of Liquid Biopsy in Endometrial Cancer. <i>Cancers</i> , 2021, 13, 5731.	1.7	13
12	microRNA Expression Profile in Single Hormone Receptor-Positive Breast Cancers Is Mainly Dependent on HER2 Status: A Pilot Study. <i>Diagnostics</i> , 2020, 10, 617.	1.3	7
13	MAML2 rearrangement as a useful diagnostic marker discriminating between Warthin tumour and Warthin-like mucoepidermoid carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 393-400.	1.4	15
14	Liquid biopsy for minimally invasive heart transplant monitoring: a pilot study. <i>Journal of Clinical Pathology</i> , 2020, 73, 507-510.	1.0	4
15	Expression of Female Sex Hormone Receptors, Connective Tissue Growth Factor and HER2 in Gallbladder Cancer. <i>Scientific Reports</i> , 2020, 10, 1871.	1.6	7
16	Medullary thyroid carcinoma of unknown primary origin with synchronous finding of papillary thyroid carcinoma. <i>Endokrynologia Polska</i> , 2020, 71, 200-201.	0.3	1
17	Primarily resectable pancreatic adenocarcinoma: to operate or to refer the patient to an oncologist?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 95-102.	2.0	6
18	MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients. <i>Archives of Medical Science</i> , 2019, 15, 504-512.	0.4	49

#	ARTICLE	IF	CITATIONS
19	Consistency in biomarkers expression between matched tissue microarray cores from primary gallbladder and ovarian cancers. <i>Oncology in Clinical Practice</i> , 2019, 15, 85-88.	0.1	1
20	Genomic characterization of brain metastases (BM) in high-grade serous ovarian cancer (HGSOC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e13580-e13580.	0.8	0
21	Clinical neuropathology of brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 477-534.	1.0	6
22	Isoprostanes as potential cerebral vasospasm biomarkers. <i>Neurologia I Neurochirurgia Polska</i> , 2018, 52, 643-651.	0.6	4
23	Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach. , 2018, 37, 166-177.		9
24	Bioimaging and surgery of brain tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 145, 535-545.	1.0	4
25	Recurrent Pineocytomalike Papillary Tumor of The Pineal Region: A Case Report and Literature Review. <i>World Neurosurgery</i> , 2018, 120, 1-14.	0.7	3
26	Urinary F2-Isoprostane Concentration as a Poor Prognostic Factor After Subarachnoid Hemorrhage.. <i>World Neurosurgery</i> , 2017, 107, 185-193.	0.7	6
27	Validation of nuclear STAT6 immunostaining as a diagnostic marker of meningeal solitary fibrous tumor (SFT)/hemangiopericytoma. , 2017, 36, 56-59.		19
28	KINFix – A formalin-free non-commercial fixative optimized for histological, immunohistochemical and molecular analyses of neurosurgical tissue specimens. , 2016, 35, 3-12.		12
29	BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 7-14.	1.9	16
30	Prognostic role of tumour-infiltrating inflammatory cells in brain tumours. <i>Current Opinion in Neurology</i> , 2015, 28, 647-658.	1.8	33
31	Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions. , 2015, 34, 250-257.		42
32	The Failure in the Stabilization of Glioblastoma-Derived Cell Lines: Spontaneous In Vitro Senescence as the Main Culprit. <i>PLoS ONE</i> , 2014, 9, e87136.	1.1	22
33	Different mutational characteristics of TSG in cell lines and surgical specimens. <i>Tumor Biology</i> , 2014, 35, 11311-11318.	0.8	2
34	PIN3 duplication may be partially responsible for TP53 haploinsufficiency. <i>BMC Cancer</i> , 2014, 14, 669.	1.1	4
35	Reduced expression of ELAVL4 in male meningioma patients. <i>Brain Tumor Pathology</i> , 2013, 30, 160-166.	1.1	13
36	Screening for EGFR Amplifications with a Novel Method and Their Significance for the Outcome of Glioblastoma Patients. <i>PLoS ONE</i> , 2013, 8, e65444.	1.1	29

#	ARTICLE	IF	CITATIONS
37	Association of loss of heterozygosity with shorter survival in primary glioblastoma patients. Polish Journal of Pathology, 2013, 4, 268-275.	0.1	12
38	EGFRvIII—a stable target for anti-EGFRvIII therapy. Anticancer Research, 2013, 33, 5343-8.	0.5	4
39	Glioblastoma specimens with TP53 mutations do not show EGFRvIII amplification. Cancer Genetics, 2011, 204, 282-283.	0.2	3
40	Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions. British Journal of Cancer, 2011, 104, 968-970.	2.9	76
41	Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies. Journal of Neuro-Oncology, 2011, 102, 395-407.	1.4	27
42	Limited importance of the dominant-negative effect of TP53 missense mutations. BMC Cancer, 2011, 11, 243.	1.1	7
43	Detection of P53 mutations in different cancer types is improved by cDNA sequencing. Oncology Letters, 2010, 1, 717-721.	0.8	5
44	PARP inhibitors beyond BRCA-mutated cancers: precision medicine at the crossroads. Precision Cancer Medicine, 0, 4, 19-19.	1.8	2